Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash & Equivalents (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Cash & Equivalents for 3 consecutive years, with $108.0 million as the latest value for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 168.42% year-over-year to $108.0 million; the TTM value through Dec 2025 reached $108.0 million, up 168.42%, while the annual FY2025 figure was $108.0 million, 168.42% up from the prior year.
  • Cash & Equivalents hit $108.0 million in Q4 2025 for Artiva Biotherapeutics, up from $25.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $108.0 million in Q4 2025 and bottomed at $25.5 million in Q3 2025.
  • Average Cash & Equivalents over 3 years is $49.5 million, with a median of $48.2 million recorded in 2024.
  • On a YoY basis, Cash & Equivalents climbed as much as 168.42% in 2025 and fell as far as 54.35% in 2025.
  • Artiva Biotherapeutics' Cash & Equivalents stood at $53.5 million in 2023, then decreased by 24.8% to $40.2 million in 2024, then surged by 168.42% to $108.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $108.0 million, $25.5 million, and $28.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.